Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,861
archived clinical trials in
Bladder Cancer

A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT
A Phase 1/2, Placebo-Controlled, Randomized Study to Evaluate the Safety, Immune Response and Clinical Activity of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer Who Have Undergone Transurethral Resection of Bladder Tumor (TURBT)
Status: Enrolling
Updated:  12/31/1969
Montefiore Medical Center
1293
mi
from
Bronx, NY
A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT
A Phase 1/2, Placebo-Controlled, Randomized Study to Evaluate the Safety, Immune Response and Clinical Activity of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer Who Have Undergone Transurethral Resection of Bladder Tumor (TURBT)
Status: Enrolling
Updated: 12/31/1969
Montefiore Medical Center
1293
mi
from
Bronx, NY
Click here to add this to my saved trials
A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT
A Phase 1/2, Placebo-Controlled, Randomized Study to Evaluate the Safety, Immune Response and Clinical Activity of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer Who Have Undergone Transurethral Resection of Bladder Tumor (TURBT)
Status: Enrolling
Updated:  12/31/1969
University of North Carolina at Chapel Hill
1038
mi
from
Chapel Hill, NC
A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT
A Phase 1/2, Placebo-Controlled, Randomized Study to Evaluate the Safety, Immune Response and Clinical Activity of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer Who Have Undergone Transurethral Resection of Bladder Tumor (TURBT)
Status: Enrolling
Updated: 12/31/1969
University of North Carolina at Chapel Hill
1038
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT
A Phase 1/2, Placebo-Controlled, Randomized Study to Evaluate the Safety, Immune Response and Clinical Activity of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer Who Have Undergone Transurethral Resection of Bladder Tumor (TURBT)
Status: Enrolling
Updated:  12/31/1969
Thomas Jefferson University
1225
mi
from
Philadelphia, PA
A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT
A Phase 1/2, Placebo-Controlled, Randomized Study to Evaluate the Safety, Immune Response and Clinical Activity of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer Who Have Undergone Transurethral Resection of Bladder Tumor (TURBT)
Status: Enrolling
Updated: 12/31/1969
Thomas Jefferson University
1225
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT
A Phase 1/2, Placebo-Controlled, Randomized Study to Evaluate the Safety, Immune Response and Clinical Activity of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer Who Have Undergone Transurethral Resection of Bladder Tumor (TURBT)
Status: Enrolling
Updated:  12/31/1969
Carolina Urologic Research Center
1099
mi
from
Myrtle Beach, SC
A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT
A Phase 1/2, Placebo-Controlled, Randomized Study to Evaluate the Safety, Immune Response and Clinical Activity of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer Who Have Undergone Transurethral Resection of Bladder Tumor (TURBT)
Status: Enrolling
Updated: 12/31/1969
Carolina Urologic Research Center
1099
mi
from
Myrtle Beach, SC
Click here to add this to my saved trials
A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT
A Phase 1/2, Placebo-Controlled, Randomized Study to Evaluate the Safety, Immune Response and Clinical Activity of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer Who Have Undergone Transurethral Resection of Bladder Tumor (TURBT)
Status: Enrolling
Updated:  12/31/1969
Urology of North Texas
347
mi
from
Dallas, TX
A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT
A Phase 1/2, Placebo-Controlled, Randomized Study to Evaluate the Safety, Immune Response and Clinical Activity of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer Who Have Undergone Transurethral Resection of Bladder Tumor (TURBT)
Status: Enrolling
Updated: 12/31/1969
Urology of North Texas
347
mi
from
Dallas, TX
Click here to add this to my saved trials
A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT
A Phase 1/2, Placebo-Controlled, Randomized Study to Evaluate the Safety, Immune Response and Clinical Activity of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer Who Have Undergone Transurethral Resection of Bladder Tumor (TURBT)
Status: Enrolling
Updated:  12/31/1969
Urology of Virginia, PLLC
1196
mi
from
Virginia Beach, VA
A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT
A Phase 1/2, Placebo-Controlled, Randomized Study to Evaluate the Safety, Immune Response and Clinical Activity of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer Who Have Undergone Transurethral Resection of Bladder Tumor (TURBT)
Status: Enrolling
Updated: 12/31/1969
Urology of Virginia, PLLC
1196
mi
from
Virginia Beach, VA
Click here to add this to my saved trials
A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT
A Phase 1/2, Placebo-Controlled, Randomized Study to Evaluate the Safety, Immune Response and Clinical Activity of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer Who Have Undergone Transurethral Resection of Bladder Tumor (TURBT)
Status: Enrolling
Updated:  12/31/1969
University of Massachusetts
1408
mi
from
Worcester, MA
A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT
A Phase 1/2, Placebo-Controlled, Randomized Study to Evaluate the Safety, Immune Response and Clinical Activity of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer Who Have Undergone Transurethral Resection of Bladder Tumor (TURBT)
Status: Enrolling
Updated: 12/31/1969
University of Massachusetts
1408
mi
from
Worcester, MA
Click here to add this to my saved trials
A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT
A Phase 1/2, Placebo-Controlled, Randomized Study to Evaluate the Safety, Immune Response and Clinical Activity of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer Who Have Undergone Transurethral Resection of Bladder Tumor (TURBT)
Status: Enrolling
Updated:  12/31/1969
M.D. Anderson Cancer Center
572
mi
from
Houston, TX
A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT
A Phase 1/2, Placebo-Controlled, Randomized Study to Evaluate the Safety, Immune Response and Clinical Activity of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer Who Have Undergone Transurethral Resection of Bladder Tumor (TURBT)
Status: Enrolling
Updated: 12/31/1969
M.D. Anderson Cancer Center
572
mi
from
Houston, TX
Click here to add this to my saved trials
A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT
A Phase 1/2, Placebo-Controlled, Randomized Study to Evaluate the Safety, Immune Response and Clinical Activity of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer Who Have Undergone Transurethral Resection of Bladder Tumor (TURBT)
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
414
mi
from
Saint Louis, MO
A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT
A Phase 1/2, Placebo-Controlled, Randomized Study to Evaluate the Safety, Immune Response and Clinical Activity of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer Who Have Undergone Transurethral Resection of Bladder Tumor (TURBT)
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
414
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG
A Randomized, Prospective, Phase II Study to Determine the Efficacy of Bacillus Calmette-Guerin (BCG) Given in Combination With PANVAC[TM] Versus BCG Given Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer (NMIBC) Who Failed at Least 1 Induction Course of BCG
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
1123
mi
from
Bethesda, MD
Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG
A Randomized, Prospective, Phase II Study to Determine the Efficacy of Bacillus Calmette-Guerin (BCG) Given in Combination With PANVAC[TM] Versus BCG Given Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer (NMIBC) Who Failed at Least 1 Induction Course of BCG
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
1123
mi
from
Bethesda, MD
Click here to add this to my saved trials
Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG
A Randomized, Prospective, Phase II Study to Determine the Efficacy of Bacillus Calmette-Guerin (BCG) Given in Combination With PANVAC[TM] Versus BCG Given Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer (NMIBC) Who Failed at Least 1 Induction Course of BCG
Status: Enrolling
Updated:  12/31/1969
The Cancer Institute of New Jersey
1263
mi
from
New Brunswick, NJ
Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG
A Randomized, Prospective, Phase II Study to Determine the Efficacy of Bacillus Calmette-Guerin (BCG) Given in Combination With PANVAC[TM] Versus BCG Given Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer (NMIBC) Who Failed at Least 1 Induction Course of BCG
Status: Enrolling
Updated: 12/31/1969
The Cancer Institute of New Jersey
1263
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Immunoscore in Rectal Cancer
A Study to Determine the Immunopheotype of Locally Advanced Rectal Adenocarcinoma and Its Correlation With the Efficacy of Neoadjuvant Chemoradiotherapy
Status: Enrolling
Updated:  12/31/1969
Providence Health & Services
1383
mi
from
Portland, OR
Immunoscore in Rectal Cancer
A Study to Determine the Immunopheotype of Locally Advanced Rectal Adenocarcinoma and Its Correlation With the Efficacy of Neoadjuvant Chemoradiotherapy
Status: Enrolling
Updated: 12/31/1969
Providence Health & Services
1383
mi
from
Portland, OR
Click here to add this to my saved trials
Immunoscore in Rectal Cancer
A Study to Determine the Immunopheotype of Locally Advanced Rectal Adenocarcinoma and Its Correlation With the Efficacy of Neoadjuvant Chemoradiotherapy
Status: Enrolling
Updated:  12/31/1969
Oregon Health and Science University
1383
mi
from
Portland, OR
Immunoscore in Rectal Cancer
A Study to Determine the Immunopheotype of Locally Advanced Rectal Adenocarcinoma and Its Correlation With the Efficacy of Neoadjuvant Chemoradiotherapy
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Science University
1383
mi
from
Portland, OR
Click here to add this to my saved trials
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
An Integrated Phase II/III, Open Label, Randomized and Controlled Study of the Safety and Efficacy of CG0070 Adenovirus Vector Expressing GM-CSF in Patients With Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ Disease Who Have Failed BCG
Status: Enrolling
Updated:  12/31/1969
BCG Oncology
844
mi
from
Phoenix, AZ
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
An Integrated Phase II/III, Open Label, Randomized and Controlled Study of the Safety and Efficacy of CG0070 Adenovirus Vector Expressing GM-CSF in Patients With Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ Disease Who Have Failed BCG
Status: Enrolling
Updated: 12/31/1969
BCG Oncology
844
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
An Integrated Phase II/III, Open Label, Randomized and Controlled Study of the Safety and Efficacy of CG0070 Adenovirus Vector Expressing GM-CSF in Patients With Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ Disease Who Have Failed BCG
Status: Enrolling
Updated:  12/31/1969
University of California San Diego, Moores Cancer Center
1118
mi
from
La Jolla, CA
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
An Integrated Phase II/III, Open Label, Randomized and Controlled Study of the Safety and Efficacy of CG0070 Adenovirus Vector Expressing GM-CSF in Patients With Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ Disease Who Have Failed BCG
Status: Enrolling
Updated: 12/31/1969
University of California San Diego, Moores Cancer Center
1118
mi
from
La Jolla, CA
Click here to add this to my saved trials
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
An Integrated Phase II/III, Open Label, Randomized and Controlled Study of the Safety and Efficacy of CG0070 Adenovirus Vector Expressing GM-CSF in Patients With Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ Disease Who Have Failed BCG
Status: Enrolling
Updated:  12/31/1969
UCLA Institute of Urological Oncology
1168
mi
from
Los Angeles, CA
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
An Integrated Phase II/III, Open Label, Randomized and Controlled Study of the Safety and Efficacy of CG0070 Adenovirus Vector Expressing GM-CSF in Patients With Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ Disease Who Have Failed BCG
Status: Enrolling
Updated: 12/31/1969
UCLA Institute of Urological Oncology
1168
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
An Integrated Phase II/III, Open Label, Randomized and Controlled Study of the Safety and Efficacy of CG0070 Adenovirus Vector Expressing GM-CSF in Patients With Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ Disease Who Have Failed BCG
Status: Enrolling
Updated:  12/31/1969
University of California Davis Cancer Center
1281
mi
from
Sacramento, CA
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
An Integrated Phase II/III, Open Label, Randomized and Controlled Study of the Safety and Efficacy of CG0070 Adenovirus Vector Expressing GM-CSF in Patients With Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ Disease Who Have Failed BCG
Status: Enrolling
Updated: 12/31/1969
University of California Davis Cancer Center
1281
mi
from
Sacramento, CA
Click here to add this to my saved trials
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
An Integrated Phase II/III, Open Label, Randomized and Controlled Study of the Safety and Efficacy of CG0070 Adenovirus Vector Expressing GM-CSF in Patients With Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ Disease Who Have Failed BCG
Status: Enrolling
Updated:  12/31/1969
University of Chicago, Department of Surgery, Section of Urology
609
mi
from
Chicago, IL
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
An Integrated Phase II/III, Open Label, Randomized and Controlled Study of the Safety and Efficacy of CG0070 Adenovirus Vector Expressing GM-CSF in Patients With Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ Disease Who Have Failed BCG
Status: Enrolling
Updated: 12/31/1969
University of Chicago, Department of Surgery, Section of Urology
609
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
An Integrated Phase II/III, Open Label, Randomized and Controlled Study of the Safety and Efficacy of CG0070 Adenovirus Vector Expressing GM-CSF in Patients With Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ Disease Who Have Failed BCG
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Health Sciences
979
mi
from
Winston-Salem, NC
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
An Integrated Phase II/III, Open Label, Randomized and Controlled Study of the Safety and Efficacy of CG0070 Adenovirus Vector Expressing GM-CSF in Patients With Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ Disease Who Have Failed BCG
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Health Sciences
979
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
An Integrated Phase II/III, Open Label, Randomized and Controlled Study of the Safety and Efficacy of CG0070 Adenovirus Vector Expressing GM-CSF in Patients With Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ Disease Who Have Failed BCG
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University Medical Center, Department of Urologic Surgery
618
mi
from
Nashville, TN
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
An Integrated Phase II/III, Open Label, Randomized and Controlled Study of the Safety and Efficacy of CG0070 Adenovirus Vector Expressing GM-CSF in Patients With Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ Disease Who Have Failed BCG
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University Medical Center, Department of Urologic Surgery
618
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
676
mi
from
Birmingham, AL
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
676
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
Pinnacle Oncology Hematology
840
mi
from
Scottsdale, AZ
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
Pinnacle Oncology Hematology
840
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
Arizona Oncology - HOPE Wilmot
829
mi
from
Tucson, AZ
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
Arizona Oncology - HOPE Wilmot
829
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
UCLA
1177
mi
from
Los Angeles, CA
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
UCLA
1177
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
The Angeles Clinic and Research Institute - W LA Office
1180
mi
from
Los Angeles, CA
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
The Angeles Clinic and Research Institute - W LA Office
1180
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
USC Norris Cancer Center
1166
mi
from
Los Angeles, CA
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
USC Norris Cancer Center
1166
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
UCSF
1340
mi
from
San Francisco, CA
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
UCSF
1340
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente-San Marcos
1133
mi
from
San Marcos, CA
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente-San Marcos
1133
mi
from
San Marcos, CA
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
Stanford Cancer Center
1329
mi
from
Stanford, CA
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
Stanford Cancer Center
1329
mi
from
Stanford, CA
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente Oncology Clinical Trials
1327
mi
from
Vallejo, CA
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente Oncology Clinical Trials
1327
mi
from
Vallejo, CA
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
Rocky Mountain Cancer Center- Aurora
401
mi
from
Aurora, CO
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
Rocky Mountain Cancer Center- Aurora
401
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
University of Colorado
404
mi
from
Aurora, CO
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
University of Colorado
404
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
University of Connecticut Health Center
1350
mi
from
Farmington, CT
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
University of Connecticut Health Center
1350
mi
from
Farmington, CT
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
Yale Cancer Center ; Medical Oncology
1343
mi
from
New Haven, CT
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
Yale Cancer Center ; Medical Oncology
1343
mi
from
New Haven, CT
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
Georgetown University Medical Center Lombardi Cancer Center
1127
mi
from
Washington,
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
Georgetown University Medical Center Lombardi Cancer Center
1127
mi
from
Washington,
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Cancer Center
1068
mi
from
Jacksonville, FL
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Cancer Center
1068
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
Piedmont Cancer Institute, P.C.
797
mi
from
Atlanta, GA
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
Piedmont Cancer Institute, P.C.
797
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
University of Chicago; Hematology/Oncology
609
mi
from
Chicago, IL
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
University of Chicago; Hematology/Oncology
609
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
Ingalls Memorial Hospital
601
mi
from
Harvey, IL
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
Ingalls Memorial Hospital
601
mi
from
Harvey, IL
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
Indiana University Health Goshen Center For Cancer Care
689
mi
from
Goshen, IN
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
Indiana University Health Goshen Center For Cancer Care
689
mi
from
Goshen, IN
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
Norton Cancer Institute
663
mi
from
Louisville, KY
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
Norton Cancer Institute
663
mi
from
Louisville, KY
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital - Oncology
1443
mi
from
Boston, MA
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital - Oncology
1443
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
Dana Farber Cancer Inst. ; Dept. of Medical Oncology
1441
mi
from
Boston, MA
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
Dana Farber Cancer Inst. ; Dept. of Medical Oncology
1441
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
Beth Israel Deaconess Medical Center, Harvard Medical School; Department of Medicine
1441
mi
from
Boston, MA
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Medical Center, Harvard Medical School; Department of Medicine
1441
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
University of Michigan Comprehensive Cancer Center
808
mi
from
Ann Arbor, MI
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
University of Michigan Comprehensive Cancer Center
808
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
Karmanos Cancer Institute
841
mi
from
Detroit, MI
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
Karmanos Cancer Institute
841
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
Minnesota Oncology Minneapolis
550
mi
from
Minneapolis, MN
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
Minnesota Oncology Minneapolis
550
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Rochester
515
mi
from
Rochester, MN
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Rochester
515
mi
from
Rochester, MN
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
Urology Cancer Center & GU Research Network
256
mi
from
Omaha, NE
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
Urology Cancer Center & GU Research Network
256
mi
from
Omaha, NE
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
Comprehensive Cancer Centers of Nevada
970
mi
from
Las Vegas, NV
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
Comprehensive Cancer Centers of Nevada
970
mi
from
Las Vegas, NV
Click here to add this to my saved trials